TY - JOUR
T1 - Clomipramine in the treatment of patients with obsessive-compulsive disorder
AU - DeVeaugh-Geiss, Joseph
AU - Katz, Richard
AU - Landau, Phyllis
AU - Akiskal, Hagop
AU - Ananth, Jambur
AU - Ballenger, James
AU - Betts, Wilmer C.
AU - Diamond, Bruce
AU - Feiger, Alan
AU - Foa, Edna
AU - Fogelson, David
AU - Goodman, Wayne
AU - Greist, John
AU - Himmelhoch, Jonathan
AU - Hoehn-Saric, Rudolf
AU - Jenike, Michael
AU - Kim, Suck Won
AU - Liebowitz, Michael
AU - Mavissakalian, Matig
AU - Ninan, Philip
AU - Noyes, Russell
AU - Rasmussen, Steven
AU - Ringold, Alan
AU - Shear, Katherine
PY - 1991
Y1 - 1991
N2 - Two double-blind studies at 21 centers evaluated the therapeutic efficacy, safety, and tolerability of up to 300 mg/d of clomipramine hydrochloride or an equivalent number of placebo capsules in the treatment of 520 patients with obsessive-compulsive disorder, of whom 239 had had the disorder for at least 2 years (study 1) and 281 had been ill for at least 1 year (study 2). On the two principal measures of the severity of the disorder, ie, the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global Obsessive Compulsive Scale, clomipramine was significantly more effective than placebo in both studies. The mean reduction in the Yale-Brown Obsessive Compulsive Scale score at the end of 10 weeks of treatment was 38% and 44% in studies 1 and 2, respectively, for the clomipramine-treated patients and 3% and 5% for the placebo-treated patients. The drug was also found to be superior on the basis of the physicians' and patients' evaluations of global therapeutic change. The most frequently observed adverse effects during clomipramine therapy were those typically associated with tricyclic antidepressant drugs. Although uncommon, the occurrence of seizures and elevated aminotransferase values are potentially serious side effects of clomipramine. Clomipramine was generally well tolerated and was effective in reducing obsessive and compulsive symptoms.
AB - Two double-blind studies at 21 centers evaluated the therapeutic efficacy, safety, and tolerability of up to 300 mg/d of clomipramine hydrochloride or an equivalent number of placebo capsules in the treatment of 520 patients with obsessive-compulsive disorder, of whom 239 had had the disorder for at least 2 years (study 1) and 281 had been ill for at least 1 year (study 2). On the two principal measures of the severity of the disorder, ie, the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global Obsessive Compulsive Scale, clomipramine was significantly more effective than placebo in both studies. The mean reduction in the Yale-Brown Obsessive Compulsive Scale score at the end of 10 weeks of treatment was 38% and 44% in studies 1 and 2, respectively, for the clomipramine-treated patients and 3% and 5% for the placebo-treated patients. The drug was also found to be superior on the basis of the physicians' and patients' evaluations of global therapeutic change. The most frequently observed adverse effects during clomipramine therapy were those typically associated with tricyclic antidepressant drugs. Although uncommon, the occurrence of seizures and elevated aminotransferase values are potentially serious side effects of clomipramine. Clomipramine was generally well tolerated and was effective in reducing obsessive and compulsive symptoms.
UR - http://www.scopus.com/inward/record.url?scp=0026410690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026410690&partnerID=8YFLogxK
M3 - Article
C2 - 1883256
AN - SCOPUS:0026410690
VL - 48
SP - 730
EP - 738
JO - JAMA Psychiatry
JF - JAMA Psychiatry
SN - 2168-622X
IS - 8
ER -